Immunological Prognostic Factors in Multiple Myeloma

Int J Mol Sci. 2021 Mar 30;22(7):3587. doi: 10.3390/ijms22073587.

Abstract

Multiple myeloma (MM) is a plasma cell neoplasm characterized by an abnormal proliferation of clonal, terminally differentiated B lymphocytes. Current approaches for the treatment of MM focus on developing new diagnostic techniques; however, the search for prognostic markers is also crucial. This enables the classification of patients into risk groups and, thus, the selection of the most optimal treatment method. Particular attention should be paid to the possible use of immune factors, as the immune system plays a key role in the formation and course of MM. In this review, we focus on characterizing the components of the immune system that are of prognostic value in MM patients, in order to facilitate the development of new diagnostic and therapeutic directions.

Keywords: cytokines; immune cells; markers; multiple myeloma; prognostic factors.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism
  • Chemokines
  • Cytokines
  • Humans
  • Immunologic Factors / therapeutic use
  • Intercellular Signaling Peptides and Proteins
  • Interferon-gamma
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / immunology*
  • Multiple Myeloma / metabolism*
  • Prognosis
  • Tumor Necrosis Factors

Substances

  • Biomarkers, Tumor
  • Chemokines
  • Cytokines
  • Immunologic Factors
  • Intercellular Signaling Peptides and Proteins
  • Tumor Necrosis Factors
  • Interferon-gamma